• Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resulting from trauma or surgery
• Effective October 1, the add-on payment eases financial barriers, supporting broader use of RECELL
  
  
  
   

VALENCIA, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company, today announced that beginning October 1, 2025, hospitals across the U.S. will be eligible for New Technology Add-on Payment (NTAP) reimbursement from the Centers for Medicare & Medicaid Services (CMS) when RECELL is used to treat acute, non-burn trauma and surgical full-thickness wounds.

This designation will remain in effect through September 30, 2026, providing hospitals with supplemental reimbursement of up to $4,875 per case in addition to the standard CMS payment. The NTAP was granted under CMS' alternative NTAP pathway, which recognizes the transformative nature of products that have received Breakthrough Device designation from the U.S. Food and Drug Administration.